Proteolysis targeting chimeric pharmaceutical

Details Proteolysis targeting chimeric pharmaceutical Proteolysis targeting chimeric pharmaceutical

2007-04-24

2007-04-24

Chen, Stacy B. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Fusion protein or fusion polypeptide

C424S193100, C424S194100, C424S195110, C424S208100, C530S300000, C530S350000, C530S399000

Reexamination Certificate

active

10299203

ABSTRACT:
The present invention is based on the discovery of a composition that provides targeted ubiquitination. Specifically the composition contains a ubiquitin pathway protein binding moiety which recognizes a ubiquitin pathway protein and a targeting moiety which recognizes a target protein. In addition, the present invention provides libraries of compositions, where each composition contains a ubiquitin pathway protein binding moiety and a member of a molecular library. The libraries of the present invention can be used to identify proteins involved in a predetermined function of cells.

REFERENCES:
patent: 5292638 (1994-03-01), Benz et al.
patent: 6306663 (2001-10-01), Kenten et al.
patent: 6316003 (2001-11-01), Frankel et al.
patent: WO 99/13077 (1999-03-01), None
patent: WO 00/22110 (2000-04-01), None
Nawaz et al. Proteasome-dependent degradation of the human estrogen receptor, PNAS USA, Mar. 1999, vol. 96, pp. 1858-1862.
Hatakeyama et al. Ubiquitin-dependent degradation of lκBα is mediated by a ubiquitin ligase Skp1/Cul 1/F-box protein FWD1, PNAS USA (1999) 96:3859-3863.
Sakamoto et al., “Protacs: Chimeric Molecules that Target Proteins to Skp1-Cullin-F box Complex for Ubiquitination and Degradation,”PNAS, 98(15):8554-8559, (2001).
Ivan, M. et al., “HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2Sensing”,Science, vol. 292, No. 5516, pp. 464-468, 2001.
Kwon, Y.T. et al., “Bivalent Inhibitor of the N-end Rule Pathway”,J. Biol. Chem.,vol. 274, No. 25, pp. 18135-18139, 1999.
Min, J.H. et al., “Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling”,Sciencevol. 296, No. 5574, pp. 1886-1889, 2002.
Zheng, N. et al, “Structure of a c-Cbl-UbcH7 Complex: RING Domain Function in Ubiquitin-Protein Ligases”,Cellvol. 102, No. 4, pp. 533-539, 2000.
Gosink, M. and Vierstra, R., “Redirecting the specificity of ubiquitination by modifying ubiquitin-conjugating enzymes”,Proc. Natl. Acad. Sci.,vol. 92, pp. 9117-9121, 1995.
Maniatis, Tom, “A ubiquitin ligase complex essential for the Nf-κB, Wnt/Wingless, and Hedgehog signaling pathways”,Genes&Development.,vol. 13, pp. 505-510, 1999.
Weissman, A. “Regulating protein degradation by ubiquitination”,Immunology Today, vol. 18, No. 4, pp. 189-198, 1997.
Yaron, A. et al., “Identification of the receptor component of the IκBα-ubiquitin ligase”,Nature, vol. 396, No. 6711, pp. 590-594, 1998.
Yeh, Ed. et al, “Ubiquitin-like proteins: new wines in new bottles”,Gene, vol. 248, No. 1-2, pp. 1-14, 2000.
Zhou, P. et al, “Harnessing the Ubiquitination Machinery to Target the Degradation of Specific Cellular Proteins”,Molecular Cell, vol. 6, pp. 751-756, 2000.

Affiliated with

Also associated with

Rating

Proteolysis targeting chimeric pharmaceutical does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Proteolysis targeting chimeric pharmaceutical, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proteolysis targeting chimeric pharmaceutical will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3756763